Summary
Antimicrobial Resistance (AMR), is the ability of microorganisms to resist to antibiotics treatment, contributes to 700,000 deaths a year (25,000 deaths in Europe). Besides, The financial implications of AMR proliferation are devastating for the global healthcare system. The current implementation of antimicrobial stewardship programs in hospitals has not been enough to mitigate the overuse and misuse of antibiotics. Current AST (Antimicrobial Susceptibility Testing) diagnostic methods are highly accurate but take too long (a few days) forcing doctors in many case to prescribe non-personalised treatments. The overuse and misuse of antibiotics, due to the lack of efficient solutions to detect bacterial resistance at an early stage, allows the emergence of “superbugs” and the spread of the resistant bacteria in the environment resulting in more infected patients and increasing the major global threat of Antimicrobial Resistance (AMR). Nanosynex product provides a revolutionary, low-cost, ultra-fast AST (Antimicrobial Susceptibility Testing) technology that delivers results in an average of only 4 hours in average, and as little as 2 hours for certain bacteria type. Nanosynex will allow physicians to get same-day AST results and to prescribe personalised and effective antibiotic treatment, with a unique test that will save at least one day of hospitalization per patient, as well as avoid pandemics outbreaks such as the current case of COVID-19. Consequently, Nanosynex will contribute to reduce the spread of resistant bacteria and significantly reduce the large economic burden associated with antimicrobial resistance. This EIC project aims the industrialization and scalability of Nanosynex benchtop and cards, performing the clinical trials to get the CE mark for its commercialisation across the EU. Nanosynex expects to reach a positive cash flow generation by the end of 2026 in the targeted scenario, with sales of +€27.5M.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/962124 |
| Start date: | 01-10-2020 |
| End date: | 30-09-2024 |
| Total budget - Public funding: | 3 661 250,00 Euro - 2 562 875,00 Euro |
Cordis data
Original description
Antimicrobial Resistance (AMR), is the ability of microorganisms to resist to antibiotics treatment, contributes to 700,000 deaths a year (25,000 deaths in Europe). Besides, The financial implications of AMR proliferation are devastating for the global healthcare system. The current implementation of antimicrobial stewardship programs in hospitals has not been enough to mitigate the overuse and misuse of antibiotics. Current AST (Antimicrobial Susceptibility Testing) diagnostic methods are highly accurate but take too long (a few days) forcing doctors in many case to prescribe non-personalised treatments. The overuse and misuse of antibiotics, due to the lack of efficient solutions to detect bacterial resistance at an early stage, allows the emergence of “superbugs” and the spread of the resistant bacteria in the environment resulting in more infected patients and increasing the major global threat of Antimicrobial Resistance (AMR). Nanosynex product provides a revolutionary, low-cost, ultra-fast AST (Antimicrobial Susceptibility Testing) technology that delivers results in an average of only 4 hours in average, and as little as 2 hours for certain bacteria type. Nanosynex will allow physicians to get same-day AST results and to prescribe personalised and effective antibiotic treatment, with a unique test that will save at least one day of hospitalization per patient, as well as avoid pandemics outbreaks such as the current case of COVID-19. Consequently, Nanosynex will contribute to reduce the spread of resistant bacteria and significantly reduce the large economic burden associated with antimicrobial resistance. This EIC project aims the industrialization and scalability of Nanosynex benchtop and cards, performing the clinical trials to get the CE mark for its commercialisation across the EU. Nanosynex expects to reach a positive cash flow generation by the end of 2026 in the targeted scenario, with sales of +€27.5M.Status
SIGNEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
